ESPE Yearbook of Paediatric Endocrinology

Most papers selected for this chapter tackle issues with implications for clinical practice. Phase 2 and 3 long-acting GH clinical trials in GHD, SGA and even ISS children have been published in the last year. Use of the IGF-1/IGFBP-3 molar ratio has been re-proposed, with more convincing evidence, for the diagnosis of GH deficiency. An umpteenth reassuring pharma sponsored observational study on rhGH safety with short patient follow-up has been published. The safety and effic...